Get research updatesPublic study records, presented in a clearer and more patient-friendly format for mental health research discovery.
Recruiting now refers to the overall study. Local openings are shown only when the registry lists an open site.
Researchers compare two doses of icalcaprant with placebo to find out whether the medicine improves depression symptoms in adults with bipolarity type I or II. Participants take capsules for six weeks while researchers also monitor side effects.
This study evaluates the safety and effectiveness of Emraclidine for people with schizophrenia.
A Study to Assess Change in Disease Activity and Adverse Events (AEs) With Cariprazine in the Treatment of Depressive Episodes in Pediatric Participants Participants (10 to 17 Years of Age) With Bipolar I Disorder.
Read the official source — NCT04777357Researchers are comparing Cariprazine and placebo, tracking side effects to assess safety in children with bipolarity type I.
Researchers are comparing Icalcaprant and placebo to find out how the approaches affect depression symptoms in people with depression.
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Relapse Prevention Study to Evaluate the Safety and Efficacy of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease
A Multicenter, Randomized, Double-blind, Placebo-controlled, Flexible-dose Study to Assess the Efficacy, Safety, and Tolerability of ITI 1284 in Patients With Psychosis Associated With Alzheimer's Disease
A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Hallucinations and Delusions Associated With Alzheimer's Disease Psychosis
This extension study evaluates the long-term safety and tolerability of KarXT for mania or mania with mixed features in people living with bipolarity type I.
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Psychosis Associated With Alzheimer's Disease
A 12-month Open-label, Phase 4 Multicenter Safety Study to Evaluate the Effect of KarXT on Voiding Dynamics and Urological Safety
We gather information about mental health clinical trials from the public registries we index. Coverage is still expanding, so some studies may not appear yet.